Patents by Inventor Michaela Bittner

Michaela Bittner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of a fibroblast growth factor-binding protein for the treatment and diagnosis of diabetic wound healing problems
    Publication number: 20090197256
    Abstract: The present invention relates to the use of fibroblast growth factor-binding protein (FGF-BP) polypeptides, and functional variants of these polypeptides, respectively, or of nucleic acids encoding these polypeptides or variants, or of functional variants of these nucleic acids, and/or of a cell which is expressing an FGF-BP polypeptide or functional variants thereof, for treating, diagnosing and/or preventing wound healing disturbances which are characterized by a reduced quantity of FGF-BP, in particular diabetes-associated wounds, and also to the use of at least one FGF-BP polypeptide as depicted in SEQ ID No. 1 and SEQ ID No. 3 and/or of at least one FGF-BP-encoding nucleic acid as depicted in SEQ ID No. 2 and SEQ ID No.
    Type: Application
    Filed: February 5, 2008
    Publication date: August 6, 2009
    Applicant: Fraunhofer-Gesellschaft zur forderung der angewandten Forschung e.V.
    Inventors: Andreas Goppelt, Michaela Bittner
  • Use of a fibroblast growth factor-binding protein for the treatment and diagnosis of diabetic wound healing problems
    Publication number: 20060014158
    Abstract: The present invention relates to the use of fibroblast growth factor-binding protein (FGF-BP) polypeptides, and functional variants of these polypeptides, respectively, or of nucleic acids encoding these polypeptides or variants, or of functional variants of these nucleic acids, and/or of a cell which is expressing an FGF-BP polypeptide or functional variants thereof, for treating, diagnosing and/or preventing wound healing disturbances which are characterized by a reduced quantity of FGF-BP, in particular diabetes-associated wounds, and also to the use of at least one FGF-BP polypeptide as depicted in SEQ ID No. 1 and SEQ ID No. 3 and/or of at least one FGF-BP-encoding nucleic acid as depicted in SEQ ID No. 2 and SEQ ID No.
    Type: Application
    Filed: August 26, 2004
    Publication date: January 19, 2006
    Applicant: Fraunhofer-Gesellschaft zur Forderung der angewandten Forschung e.V.
    Inventors: Andreas Goppelt, Michaela Bittner